Specifically, cetuximab's stimulation of ADCC and other immunostimulatory activities (DC maturation, T-cell recruitment to the tumor, increased antigen presentation, and cytotoxic T-cell priming) are dependent on cetuximab's simultaneous binding of the EGFR and the CD16 receptor on NK cells (25). Here, EGFR is linked to neoplasm.